Related Experiment Videos
[Multicenter study of the effectiveness and tolerance of clotiazepam in cardiology]
L Colonna1, F Cozzi, F Del Citerna
1Divisione di Cardiologia, Policlinico Consorziale, Bari.
Insights
Clotiazepam effectively treated anxiety in cardiovascular disease patients, showing good safety with mild side effects. The medication demonstrated significant improvement in anxiety and cardiovascular symptoms over three weeks.
Area of Science:
- Cardiology
- Psychiatry
- Pharmacology
Background:
- Anxiety disorders frequently co-occur with cardiovascular diseases.
- Anxiolytic medications are often prescribed, necessitating safety and efficacy studies in specific patient populations.
Purpose of the Study:
- To evaluate the efficacy and safety of clotiazepam in patients with cardiovascular diseases and anxiety.
- To assess the impact of clotiazepam on anxiety symptoms and cardiovascular parameters.
Main Methods:
- A phase IV study involving 86 patients (52 female, 32 male, mean age 51 years) with cardiovascular diseases and anxiety.
- Patients received clotiazepam 5-10 mg three times daily for 3 weeks.
- Efficacy was assessed using the Hamilton psychiatric rating scale for anxiety; safety was monitored for adverse events.
Main Results:
- Clotiazepam was effective in 75% of patients, with significant reductions in Hamilton anxiety scale scores.
- Cardiovascular symptoms showed notable improvement.
- Adverse events were observed in 14% of patients, primarily drowsiness (9.3%) and asthenia (2.3%).
Conclusions:
- Clotiazepam demonstrates good safety and efficacy in treating anxiety in patients with cardiovascular diseases.
- The study supports the use of clotiazepam as a treatment option for this patient group.
- Further research could explore long-term effects and optimal dosing strategies.
Abstract:
In a phase IV study with clotiazepam 9 cardiologists were involved to treat 86 patients (52 female, 32 male, mean age 51 years) effected by cardiovascular diseases and anxiety. The dosage was 5-10 mg TID, and the treatment lasted for 3 weeks. Variations of the dosage were requested in 21% of patients and generally at the 2nd week of treatment. The safety of clotiazepam was good: only in the 14% of patients side-effects were observed (especially drowsiness 9.3% and asthenia 2.3%). Clotiazepam was judged to be effective in 75% of patients. The Hamilton psychiatric rating scale for anxiety showed a progressive decrease both of the total score and of the scores of every item; the cardiovascular symptoms particularly improved at both the controls.